Biomedical Research Education & Training
Faculty Member

Hawiger, Jacek J., M.D., Ph.D.
Distinguished Professor of Medicine
Professor of Molecular Physiology and Biophysics
Louise B. McGavock Chair

Lab Url: N/A

Phone Number: 615-343-8280

Email Address:

Hawiger, Jacek's picture
Academic history
Baccalaureate, Mickiewicz's Lyceum, Katowice, Poland
M.D., Copernicus School of Medicine, Cracow, Poland
Ph.D., National Institute of Public Health, Warsaw, Poland
M.A. (hon), Harvard University
M.D. (hon), Copernicus School of Medicine, Cracow, Poland

Office Address   Mailing Address

1161 21st Ave. South, T-1218 MCN, Nashville, TN, 37232-2363

1161 21st Ave. South, T-2222 MCN, Nashville, TN 37232-2363

Research Specialty
Inflammation, Innate Immunity, Biodefense, and Intracellular Delivery of Proteins and Peptides

Research Description
Inflammation is the main mechanism of diseases caused by microbial, autoimmune, metabolic, and physical factors. In fact, we estimate that approx. 80% of all major human diseases, including heart attacks, strokes, sepsis, and early cancer, are mediated by inflammation. Proinflammatory cues are sensed by pattern recognition receptors such as Toll-like Receptors (TLRs) that are mainstays of innate immunity. These receptors generate signals that are transduced to the nucleus by an intricate network of intracellular adaptors. We study two families of these adaptors as potential targets for anti-inflammatory therapy to prevent reprogramming of the genome toward proinflammatory phenotype.

The first family of innate immunity adaptors of intense interest is MyD88 (myeloid differentiation 88) protein and its four relatives, including MAL, TRIF and SARM. We study them by identifying their cross-talk with TLRs and with each other. For example, we identified the RDR motif in Box 2 of MyD88 TIR domain as the interactive site with some members of TLR superfamily. This site is mutated in inborn errors of innate immunity characterized by pyogenic infections. We also unraveled a new function for another adaptor SARM.

The second family of adaptors of longstanding interest to us is the so-called nuclear import machinery, known as importins or karyopherins. We provided initial evidence that by targeting them with cell-penetrating peptides, which displace nuclear import cargo from its binding pocket on importin alpha 1, we prevent nuclear delivery of proinflammatory transcription factors such as NFkappa B, AP-1, NFAT, and STAT-1. Hence, proinflammatory reprogramming of the genome is prevented in multiple cells that stop producing inflammatory, procoagulant, proapoptotic, and autoimmune mediators. We accomplished this outcome by developing an innovative platform for intracellular delivery of peptides and proteins that bypass endosomal pathway with its degradative potential. We have proven the utility of nuclear import inhibitors as cell-penetrating peptides in preclinical models of septic/toxic shock and in acute lung inflammation caused by bacterial lipopolysaccharide and superantigen as well as in chronic autoimmune diabetes model that mimics Type 1 diabetes. We extended these long-term treatment studies to a relevant model of atherosclerosis induced by Western diet in LDL receptor-negative mice. Cumulatively, these basic and translational studies provided a firm basis for the nuclear paradigm of inflammation

Finally, we continue our groundbreaking studies of intracellular protein therapy as a facile alternative of gene therapy. We have proven the utility of intracellular protein therapy by bioengineering and delivering physiologic suppressor of cytokine signaling 3 (SOCS3) to prevent or treat acute liver inflammation and apoptosis induced by microbial agents in preclinical models. We extended the anti-inflammatory action of cell-penetrating SOCS3 by engineering its long-acting form to persist 41 times longer than endogenous SOCS3. This increased stability, coupled with the capacity for rapid intracellular delivery renders the CP- SOCS3 mutant an attractive candidate for intracellular protein therapy to suppress acute and chronic inflammation induced by a variety of proinflammatory agonists in multiple organ systems.

DiGiandomenico, A, Veach, RA, Zienkiewicz, J, Moore, DJ, Wylezinski, LS, Hutchens, MA, Hawiger, J. The "genomic storm" induced by bacterial endotoxin is calmed by a nuclear transport modifier that attenuates localized and systemic inflammation. PLoS One, 9(10), e110183, 2014

Qiao, H, Liu, Y, Veach, RA, Wylezinski, L, Hawiger, J. The adaptor CRADD/RAIDD controls activation of endothelial cells by proinflammatory stimuli. J Biol Chem, 289(32), 21973-83, 2014

Liu, Y, Major, AS, Zienkiewicz, J, Gabriel, CL, Veach, RA, Moore, DJ, Collins, RD, Hawiger, J. Nuclear transport modulation reduces hypercholesterolemia, atherosclerosis, and fatty liver. J Am Heart Assoc, 2(2), e000093, 2013

Sethman, CR, Hawiger, J. The Innate Immunity Adaptor SARM Translocates to the Nucleus to Stabilize Lamins and Prevent DNA Fragmentation in Response to Pro-Apoptotic Signaling. PLoS One, 8(7), e70994, 2013

Zienkiewicz, J, Armitage, A, Hawiger, J. Targeting nuclear import shuttles, importins/karyopherins alpha by a peptide mimicking the NF??B1/p50 nuclear localization sequence. J Am Heart Assoc, 2(5), e000386, 2013

Lin, Q, Liu, Y, Moore, DJ, Elizer, SK, Veach, RA, Hawiger, J, Ruley, HE. Cutting Edge: The "Death" Adaptor CRADD/RAIDD Targets BCL10 and Suppresses Agonist-Induced Cytokine Expression in T Lymphocytes. J Immunol, 188(6), 2493-7, 2012

Veach, RA, Zienkiewicz, J, Collins, RD, Hawiger, J. Lethality in a murine model of pulmonary anthrax is reduced by combining nuclear transport modifier with antimicrobial therapy. PLoS One, 7(1), e30527, 2012 PMCID:3266913

Hawiger, J, Musser, JM. How to approach genome wars in sepsis. Crit Care, 15(6), 1007, 2011 PMCID:3266913

Fletcher, TC, DiGiandomenico, A, Hawiger, J. Extended anti-inflammatory action of a degradation-resistant mutant of cell-penetrating suppressor of cytokine signaling 3. J Biol Chem, 285(24), 18727-36, 2010 PMCID:2950856

Moore, DJ, Zienkiewicz, J, Kendall, PL, Liu, D, Liu, X, Veach, RA, Collins, RD, Hawiger, J. In vivo islet protection by a nuclear import inhibitor in a mouse model of type 1 diabetes. PLoS One, 5(10), e13235, 2010 PMCID:2950856

DiGiandomenico, A, Wylezinski, LS, Hawiger, J. Intracellular delivery of a cell-penetrating SOCS1 that targets IFN-gamma signaling. Sci Signal, 2(80), ra37, 2009 PMCID:2798805

Liu, D, Zienkiewicz, J, DiGiandomenico, A, Hawiger, J. Suppression of acute lung inflammation by intracellular peptide delivery of a nuclear import inhibitor. Mol Ther, 17(5), 796-802, 2009 PMCID:2835128

Zanchi, C, Zoja, C, Morigi, M, Valsecchi, F, Liu, XY, Rottoli, D, Locatelli, M, Buelli, S, Pezzotta, A, Mapelli, P, Geelen, J, Remuzzi, G, Hawiger, J. Fractalkine and CX3CR1 mediate leukocyte capture by endothelium in response to Shiga toxin. J Immunol, 181(2), 1460-9, 2008 PMCID:2835128

Bezbradica, JS, Gordy, LE, Stanic, AK, Dragovic, S, Hill, T, Hawiger, J, Unutmaz, D, Van Kaer, L, Joyce, S. Granulocyte-macrophage colony-stimulating factor regulates effector differentiation of invariant natural killer T cells during thymic ontogeny. Immunity, 25(3), 487-97, 2006

Jo, D, Liu, D, Yao, S, Collins, RD, Hawiger, J. Intracellular protein therapy with SOCS3 inhibits inflammation and apoptosis. Nat Med, 11(8), 892-8, 2005

Kathy Aschheim, Nadia Cervoni, Laura DeFrancesco, Teresa Moogan and Gaspar Taroncher-Oldenburg. New septic shock therapeutic?. Nature Biotechnology, 23(8), 949, 2005

Li, C, Zienkiewicz, J, Hawiger, J. Interactive sites in the MyD88 Toll/interleukin (IL) 1 receptor domain responsible for coupling to the IL1beta signaling pathway. J Biol Chem, 280(28), 26152-9, 2005

Melissa Marino. Protein therapy "SOCS" in to inflammation. The Reporter/VUMC(August 19), 2005

Liu, D, Li, C, Chen, Y, Burnett, C, Liu, XY, Downs, S, Collins, RD, Hawiger, J. Nuclear import of proinflammatory transcription factors is required for massive liver apoptosis induced by bacterial lipopolysaccharide. J Biol Chem, 279(46), 48434-42, 2004

Liu, Danya, Liu, Xue Yan, Robinson, Daniel, Burnett, Christie, Jackson, Charity, Seele, Louis, Veach, Ruth Ann, Downs, Sheila, Collins, Robert D, Ballard, Dean W, Hawiger, Jacek. Suppression of Staphylococcal Enterotoxin B-induced Toxicity by a Nuclear Import Inhibitor. J Biol Chem, 279(18), 19239-46, 2004

Veach, Ruth Ann, Liu, Danya, Yao, Shan, Chen, Yiliu, Liu, Xue Yan, Downs, Sheila, Hawiger, Jacek. Receptor/transporter-independent targeting of functional peptides across the plasma membrane. J Biol Chem, 279(12), 11425-31, 2004

Hawiger J. Peptide/Protein Delivery. Encyclopedia of Molecular Medicine, John Wiley and Sons: Set ISBN 0-471-37494-6, 5, 2002

Hawiger, J. Innate immunity and inflammation: a transcriptional paradigm. Immunol Res, 23(2-3), 99-109, 2001

Oltz, E M, Hawiger, J. Immunology at Vanderbilt University. Immunol Res, 23(2-3), 97-8, 2001

Yan Liu, X, Robinson, D, Veach, R A, Liu, D, Timmons, S, Collins, R D, Hawiger, J. Peptide-directed suppression of a pro-inflammatory cytokine response. J Biol Chem, 275(22), 16774-8, 2000

Hawiger, J. Noninvasive intracellular delivery of functional peptides and proteins. Curr Opin Chem Biol, 3(1), 89-94, 1999

Hawiger, J, Veach, R A, Liu, X Y, Timmons, S, Ballard, D W. IkappaB kinase complex is an intracellular target for endotoxic lipopolysaccharide in human monocytic cells. Blood, 94(5), 1711-6, 1999

Ware, S, Donahue, J P, Hawiger, J, Anderson, W F. Structure of the fibrinogen gamma-chain integrin binding and factor XIIIa cross-linking sites obtained through carrier protein driven crystallization. Protein Sci, 8(12), 2663-71, 1999 PMCID:2144222

Chu, Z L, DiDonato, J A, Hawiger, J, Ballard, D W. The tax oncoprotein of human T-cell leukemia virus type 1 associates with and persistently activates IkappaB kinases containing IKKalpha and IKKbeta. J Biol Chem, 273(26), 15891-4, 1998

Torgerson, T R, Colosia, A D, Donahue, J P, Lin, Y Z, Hawiger, J. Regulation of NF-kappa B, AP-1, NFAT, and STAT1 nuclear import in T lymphocytes by noninvasive delivery of peptide carrying the nuclear localization sequence of NF-kappa B p50. J Immunol, 161(11), 6084-92, 1998

Zhang, L, Torgerson, T R, Liu, X Y, Timmons, S, Colosia, A D, Hawiger, J, Tam, J P. Preparation of functionally active cell-permeable peptides by single-step ligation of two peptide modules. Proc Natl Acad Sci U S A, 95(16), 9184-9, 1998 PMCID:21313

Hawiger, J. Cellular import of functional peptides to block intracellular signaling. Curr Opin Immunol, 9(2), 189-94, 1997

Lin, Y Z, Yao, S Y, Hawiger, J. Role of the nuclear localization sequence in fibroblast growth factor-1-stimulated mitogenic pathways. J Biol Chem, 271(10), 5305-8, 1996

Liu, K Y, Timmons, S, Lin, Y Z, Hawiger, J. Identification of a functionally important sequence in the cytoplasmic tail of integrin beta 3 by using cell-permeable peptide analogs. Proc Natl Acad Sci U S A, 93(21), 11819-24, 1996 PMCID:38142

Donald, R, Ballard, D W, Hawiger, J. Proteolytic processing of NF-kappa B/I kappa B in human monocytes. ATP-dependent induction by pro-inflammatory mediators. J Biol Chem, 270(1), 9-12, 1995

Hawiger, J. Adhesive ends of fibrinogen and its antiadhesive peptides: the end of a sage. Semin Hematol, 32(2), 99-109, 1995

Hawiger, J. Mechanisms involved in platelet vessel wall interaction. Thromb Haemost, 74(1), 369-72, 1995

Lin, Y Z, Yao, S Y, Veach, R A, Torgerson, T R, Hawiger, J. Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J Biol Chem, 270(24), 14255-8, 1995

Donahue, J P, Patel, H, Anderson, W F, Hawiger, J. Three-dimensional structure of the platelet integrin recognition segment of the fibrinogen gamma chain obtained by carrier protein-driven crystallization. Proc Natl Acad Sci U S A, 91(25), 12178-82, 1994 PMCID:45400

Donahue, J P, Sugg, N, Hawiger, J. The integrin alpha v gene: identification and characterization of the promoter region. Biochim Biophys Acta, 1219(1), 228-32, 1994

Shepherd, J T, Bergan, J J, Cohen, R A, Hawiger, J J, Hillis, L D, Katzen, B T, Mohr, J P. Report of the Task Force on Vascular Medicine. Circulation, 89(1), 532-5, 1994

Cordle, S R, Donald, R, Read, M A, Hawiger, J. Lipopolysaccharide induces phosphorylation of MAD3 and activation of c-Rel and related NF-kappa B proteins in human monocytic THP-1 cells. J Biol Chem, 268(16), 11803-10, 1993

Read, M A, Cordle, S R, Veach, R A, Carlisle, C D, Hawiger, J. Cell-free pool of CD14 mediates activation of transcription factor NF-kappa B by lipopolysaccharide in human endothelial cells. Proc Natl Acad Sci U S A, 90(21), 9887-91, 1993 PMCID:47677

Blumenstein, M, Matsueda, G R, Timmons, S, Hawiger, J. A beta-turn is present in the 392-411 segment of the human fibrinogen gamma-chain. Effects of structural changes in this segment on affinity to antibody 4A5. Biochemistry, 31(44), 10692-8, 1992

Hawiger, J. Introduction to platelet structural and functional organization. Methods Enzymol, 215, 3-5, 1992

Hawiger, J. Repertoire of platelet receptors. Methods Enzymol, 215, 131-6, 1992

Hawiger, J, Timmons, S. Binding of fibrinogen and von Willebrand factor to platelet glycoprotein IIb-IIIa complex. Methods Enzymol, 215, 228-43, 1992

Chen, C S, Hawiger, J. Reactivity of synthetic peptide analogs of adhesive proteins in regard to the interaction of human endothelial cells with extracellular matrix. Blood, 77(10), 2200-6, 1991

Hawiger, J. Adhesive interactions of platelets and their blockade. Ann N Y Acad Sci, 614, 270-8, 1991

Shiba, E, Lindon, J N, Kushner, L, Matsueda, G R, Hawiger, J, Kloczewiak, M, Kudryk, B, Salzman, E W. Antibody-detectable changes in fibrinogen adsorption affecting platelet activation on polymer surfaces. Am J Physiol, 260(5 Pt 1), C965-74, 1991

Bauer, K A, Kass, B L, ten Cate, H, Hawiger, J J, Rosenberg, R D. Factor IX is activated in vivo by the tissue factor mechanism. Blood, 76(4), 731-6, 1990

Grabarek, J, Her, G R, Reinhold, V N, Hawiger, J. Endotoxic lipid A interaction with human platelets. Structure-function analysis of lipid A homologs obtained from Salmonella minnesota Re595 lipopolysaccharide. J Biol Chem, 265(14), 8117-21, 1990

Johnson, R S, Her, G R, Grabarek, J, Hawiger, J, Reinhold, V N. Structural characterization of monophosphoryl lipid A homologs obtained from Salmonella minnesota Re595 lipopolysaccharide. J Biol Chem, 265(14), 8108-16, 1990

Romano, M, Hawiger, J. Interaction of endotoxic lipid A and lipid X with purified human platelet protein kinase C. J Biol Chem, 265(3), 1765-70, 1990

Bauer, K A, Kass, B L, ten Cate, H, Bednarek, M A, Hawiger, J J, Rosenberg, R D. Detection of factor X activation in humans. Blood, 74(6), 2007-15, 1989

Donaldson, D J, Mahan, J T, Amrani, D, Hawiger, J. Fibrinogen-mediated epidermal cell migration: structural correlates for fibrinogen function. J Cell Sci, 94 ( Pt 1), 101-8, 1989

Hawiger, J. Platelet secretory pathways: an overview. Methods Enzymol, 169, 191-5, 1989

Hawiger, J, Kloczewiak, M, Bednarek, M A, Timmons, S. Platelet receptor recognition domains on the alpha chain of human fibrinogen: structure-function analysis. Biochemistry, 28(7), 2909-14, 1989

Kloczewiak, M, Timmons, S, Bednarek, M A, Sakon, M, Hawiger, J. Platelet receptor recognition domain on the gamma chain of human fibrinogen and its synthetic peptide analogues. Biochemistry, 28(7), 2915-9, 1989

Timmons, S, Bednarek, M A, Kloczewiak, M, Hawiger, J. Antiplatelet 'hybrid' peptides analogous to receptor recognition domains on gamma and alpha chains of human fibrinogen. Biochemistry, 28(7), 2919-23, 1989

Timmons, S, Hawiger, J. Isolation of human platelets by albumin gradient and gel filtration. Methods Enzymol, 169, 11-21, 1989

Weiss, H J, Hawiger, J, Ruggeri, Z M, Turitto, V T, Thiagarajan, P, Hoffmann, T. Fibrinogen-independent platelet adhesion and thrombus formation on subendothelium mediated by glycoprotein IIb-IIIa complex at high shear rate. J Clin Invest, 83(1), 288-97, 1989 PMCID:303673

Grabarek, J, Timmons, S, Hawiger, J. Modulation of human platelet protein kinase C by endotoxic lipid A. J Clin Invest, 82(3), 964-71, 1988 PMCID:303609

Hawiger, J. Formation and regulation of platelet and fibrin hemostatic plug. Hum Pathol, 18(2), 111-22, 1987

Hawiger, J. Macromolecules that link platelets following vessel wall injury. Ann N Y Acad Sci, 509, 131-41, 1987

Hawiger, J. Dr. Mario Baldini (January 15, 1917-August 4, 1986). Thromb Res, 47(1), 1-3, 1987

Kloczewiak, M, Timmons, S, Hawiger, J. Reactivity of chemically cross-linked fibrinogen and its fragments D toward the staphylococcal clumping receptor. Biochemistry, 26(19), 6152-6, 1987

McManama, G, Lindon, J N, Kloczewiak, M, Smith, M A, Ware, J A, Hawiger, J, Merrill, E W, Salzman, E W. Platelet aggregation by fibrinogen polymers crosslinked across the E domain. Blood, 68(2), 363-71, 1986

Timmons, S, Hawiger, J. von Willebrand factor can substitute for plasma fibrinogen in ADP-induced platelet aggregation. Trans Assoc Am Physicians, 99, 226-35, 1986

Timmons, S, Huzoor-Akbar, , Grabarek, J, Kloczewiak, M, Hawiger, J. Mechanism of human platelet activation by endotoxic glycolipid-bearing mutant Re595 of Salmonella minnesota. Blood, 68(5), 1015-23, 1986

Kloczewiak, M, Timmons, S, Lukas, T J, Hawiger, J. Platelet receptor recognition site on human fibrinogen. Synthesis and structure-function relationship of peptides corresponding to the carboxy-terminal segment of the gamma chain. Biochemistry, 23(8), 1767-74, 1984

Nachman, R L, Leung, L L, Kloczewiak, M, Hawiger, J. Complex formation of platelet membrane glycoproteins IIb and IIIa with the fibrinogen D domain. J Biol Chem, 259(13), 8584-8, 1984

Sakon, M, Hawiger, J. Mechanism triggering platelet hemostatic plug formation in vivo. Trans Assoc Am Physicians, 97, 311-8, 1984

Timmons, S, Kloczewiak, M, Hawiger, J. ADP-dependent common receptor mechanism for binding of von Willebrand factor and fibrinogen to human platelets. Proc Natl Acad Sci U S A, 81(15), 4935-9, 1984 PMCID:391607

FitzGerald, G A, Oates, J A, Hawiger, J, Maas, R L, Roberts, L J, Lawson, J A, Brash, A R. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest, 71(3), 676-88, 1983 PMCID:436917

Hawiger, J, Kloczewiak, M, Timmons, S, Strong, D, Doolittle, R F. Interaction of fibrinogen with staphylococcal clumping factor and with platelets. Ann N Y Acad Sci, 408, 521-35, 1983

Huddleston, C B, Lupinetti, F M, Laws, K H, Collins, J C, Clanton, J A, Hawiger, J J, Oates, J A, Hammon, J W. The effects of RO-22-4679, a thromboxane synthetase inhibitor, on ventricular fibrillation induced by coronary artery occlusion in conscious dogs. Circ Res, 52(5), 608-13, 1983

Kloczewiak, M, Timmons, S, Hawiger, J. Recognition site for the platelet receptor is present on the 15-residue carboxy-terminal fragment of the gamma chain of human fibrinogen and is not involved in the fibrin polymerization reaction. Thromb Res, 29(2), 249-55, 1983

Fujimoto, T, Hawiger, J. Adenosine diphosphate induces binding of von Willebrand factor to human platelets. Nature, 297(5862), 154-6, 1982

Fujimoto, T, Ohara, S, Hawiger, J. Thrombin-induced exposure and prostacyclin inhibition of the receptor for factor VIII/von Willebrand factor on human platelets. J Clin Invest, 69(6), 1212-22, 1982 PMCID:370193

Graber, S E, Hawiger, J. Evidence that changes in platelet cyclic AMP levels regulate the fibrinogen receptor on human platelets. J Biol Chem, 257(24), 14606-9, 1982

Hawiger, J, Timmons, S, Kloczewiak, M, Strong, D D, Doolittle, R F. Gamma and alpha chains of human fibrinogen possess sites reactive with human platelet receptors. Proc Natl Acad Sci U S A, 79(6), 2068-71, 1982 PMCID:346124

Hawiger, J, Timmons, S, Strong, D D, Cottrell, B A, Riley, M, Doolittle, R F. Identification of a region of human fibrinogen interacting with staphylococcal clumping factor. Biochemistry, 21(6), 1407-13, 1982

Kloczewiak, M, Timmons, S, Hawiger, J. Localization of a site interacting with human platelet receptor on carboxy-terminal segment of human fibrinogen gamma chain. Biochem Biophys Res Commun, 107(1), 181-7, 1982

Strong, D D, Laudano, A P, Hawiger, J, Doolittle, R F. Isolation, characterization, and synthesis of peptides from human fibrinogen that block the staphylococcal clumping reaction and construction of a synthetic clumping particle. Biochemistry, 21(6), 1414-20, 1982

Des Prez, R M, Steckley, S, Stroud, R M, Hawiger, J. Interaction of Histoplasma capsulatum with human platelets. J Infect Dis, 142(1), 32-9, 1980

Hawiger, J, Parkinson, S, Timmons, S. Prostacyclin inhibits mobilisation of fibrinogen-binding sites on human ADP- and thrombin-treated platelets. Nature, 283(5743), 195-7, 1980

Robertson, R M, Robertson, D, Friesinger, G C, Timmons, S, Hawiger, J. Platelet aggregates in peripheral and coronary-sinus blood in patients with spontaneous coronary-artery spasm. Lancet, 2(8199), 829-31, 1980

Schwartz, M B, Hawiger, J, Timmons, S, Friesinger, G C. Platelet aggregates in ischemic heart disease. Thromb Haemost, 43(3), 185-8, 1980

Cheng, C M, Hawiger, J. Affinity isolation and characterization of immunoglobulin G Fc fragment-binding glycoprotein from human blood platelets. J Biol Chem, 254(7), 2165-7, 1979

Hawiger, J, Steckley, S, Hammond, D, Cheng, C, Timmons, S, Glick, A D, Des Prez, R M. Staphylococci-induced human platelet injury mediated by protein A and immunoglobulin G Fc fragment receptor. J Clin Invest, 64(4), 931-7, 1979 PMCID:372201

Hawiger, J, Hammond, D K, Timmons, S, Budzynski, A Z. Interaction of human fibrinogen with staphylococci: presence of a binding region on normal and abnormal fibrinogen variants and fibrinogen derivatives. Blood, 51(5), 799-812, 1978

Timmons, S, Hawiger, J. Separation of human platelets from plasma proteins including factor VIII VWF by a combined albumin gradient-gel filtration method using HEPES buffer. Thromb Res, 12(2), 297-306, 1978

Hawiger, J, Hawiger, A, Steckley, S, Timmons, S, Cheng, C. Membrane changes in human platelets induced by lipopolysaccharide endotoxin. Br J Haematol, 35(2), 285-99, 1977

Hawiger, J. Disseminated intravascular coagulation in patients with infections: diagnostic and therapeutic approach. Mater Med Pol, 8(2), 206-12, 1976

Niewiarowski, S, Lowery, C T, Hawiger, J, Millman, M, Timmons, S. Immunoassay of human platelet factor 4(PF4, antiheparin factor) by radial immunodiffusion. J Lab Clin Med, 87(4), 720-33, 1976

Des Prez, R M, Bryan, C S, Hawiger, J, Colley, D G. Function of the classical and alternate pathways of human complement in serum treated with ethylene glycol tetraacetic acid and MgCl2-ethylene glycol tetraacetic acid. Infect Immun, 11(6), 1235-43, 1975 PMCID:415205

Hawiger, A, Hawiger, J, Timmons, S, Steckley, S, Cheng, C. Proceedings: The role of membrane receptors in pathways of human platelet activation by endotoxin and other microbial products. Thromb Diath Haemorrh, 34(2), 594, 1975

Hawiger, J, Hammond, D K, Timmons, S. Human fibrinogen possesses binding site for staphyococci on Aalpha and Bbeta polypeptide chains. Nature, 258(5536), 643-5, 1975

Hawiger, J, Hammond, D K, Timmons, S. Proceedings: Pathobiology of human fibrinogen. Binding site for staphylococci on Aalpha and Bbeta chains of fibrinogen molecule. Thromb Diath Haemorrh, 34(1), 324-5, 1975

Hawiger, J, Hawiger, A, Timmons, S. Endotoxin-sensitive membrane component of human platelets. Nature, 256(5513), 125-7, 1975

Graybill, J R, Hawiger, J, Des Prez, R M. Complement and coagulation in Rocky Mountain spotted fever. South Med J, 66(4), 410-3, 1973

Hawiger, J, Timmons, S. Dynamic changes in the membrane of leukocyte lysosomes detected with fluorescent probe and accompanied by release of lysosomal enzymes. Biochem Biophys Res Commun, 55(4), 1278-84, 1973

Satterwhite, T K, Hawiger, J, Burklow, S L, Koenig, M G. Degradation products of fibrinogen and fibrin in bacteremia due to gram-negative rods. J Infect Dis, 127(4), 437-41, 1973

Hawiger, J, Hawiger, A, Koenig, M G. Activation of lysosomal enzymes in polymorphonuclear leukocytic granules: the role of phospholipid-protein interaction. Yale J Biol Med, 45(1), 42-8, 1972 PMCID:2591777

Hawiger, J, Marney, S R, Colley, D G, Des Prez, R M. Complement-dependent platelet injury by staphylococcal protein A. J Exp Med, 136(1), 68-80, 1972 PMCID:2139193

Hawiger, J, Hawiger, A, Koenig, M G. Staphylococcal clumping and fibrinogen and fibrin degradation products in inflammatory exudate. Proc Soc Exp Biol Med, 136(1), 132-6, 1971

Hawiger, J, Niewiarowski, S, Gurewich, V, Thomas, D P. Measurement of fibrinogen and fibrin degradation products in serum by staphylococcal clumping test. J Lab Clin Med, 75(1), 93-108, 1970

B??br, J, Hawiger, J, Janu??, S, Sznapka, L, Kalita, S. [Intradepartmental infection in a children''s clinic. Pol Tyg Lek, 24(38), 1452-5, 1969

Hawiger, J, Collins, R D, Horn, R G. Precipitation of soluble fibrin monomer complexes by lysosomal protein fraction of polymorphonuclear leukocytes. Proc Soc Exp Biol Med, 131(2), 349-53, 1969

Hawiger, J, Collins, R D, Horn, R G, Koenig, M G. Interaction of artificial phospholipid membranes with isolated polymorphonuclear leucocytic granules. Nature, 222(190), 276-8, 1969

Hawiger, J, Horn, R G, Koenig, M G, Collins, R D. Activation and release of lysosomal enzymes from isolated leukocytic granules by liposomes. A proposed model for degranulation in polymorphonuclear leukocytes. Yale J Biol Med, 42(2), 57-70, 1969 PMCID:2591583

Horn, R G, Hawiger, J, Collins, R D. Electron microscopy of fibrin-like precipitate formed during the paracoagulation reaction between soluble fibrin monomer complexes and protamine sulphate. Br J Haematol, 17(5), 463-6, 1969

Zak, C, Hawiger, J, Jeljaszewicz, J. [Susceptibility of Staphylococcus aureus to the effect of 30 antibiotics in vitro. Przegl Epidemiol, 23(2), 279-92, 1969

Zak, C, Hawiger, J, Jeljaszewicz, J. Sensitivity of Staphylococcus aureus to 30 antibiotics. Chemotherapy, 14(1), 7-21, 1969

Hawiger, J. [Staphylococcal lysozyme. 4. Lysozyme activity towards various substrates. Med Dosw Mikrobiol, 20(2), 119-24, 1968

Hawiger, J. Purification and properties of lysozyme produced by Staphylococcus aureus. J Bacteriol, 95(2), 376-84, 1968 PMCID:252029

Hawiger, J. [Staphylococcal lysozyme. II. Purification of lysozyme produced by Staphylococcus aureus 524. Med Dosw Mikrobiol, 20(1), 1-7, 1968

Hawiger, J. [Staphylococcal lysozyme. 3. Factors influencing the course of reaction of staphylococcal lysozyme. Med Dosw Mikrobiol, 20(2), 109-18, 1968

Hawiger, J. Frequency of staphylococcal lysozyme production tested by plate method. J Clin Pathol, 21(3), 390-3, 1968 PMCID:473803

Hawiger, J. [Synthesis and lysis of the cell wall of staphylococci. Postepy Hig Med Dosw, 22(2), 223-61, 1968

Lipi??ski, B, Hawiger, J, Jeljaszewicz, J. Staphylococcal clumping with soluble fibrin mmonomer complexes. J Exp Med, 126(5), 979-88, 1967 PMCID:2138412

Postdoctoral Position Available

Postdoctoral Position Details

Updated Date